TY - JOUR
T1 - C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy
AU - Cook, Casey N.
AU - Wu, Yanwei
AU - Odeh, Hana M.
AU - Gendron, Tania F.
AU - Jansen-West, Karen
AU - del Rosso, Giulia
AU - Yue, Mei
AU - Jiang, Peizhou
AU - Gomes, Edward
AU - Tong, Jimei
AU - Daughrity, Lillian M.
AU - Avendano, Nicole M.
AU - Castanedes-Casey, Monica
AU - Shao, Wei
AU - Oskarsson, Björn
AU - Tomassy, Giulio S.
AU - McCampbell, Alexander
AU - Rigo, Frank
AU - Dickson, Dennis W.
AU - Shorter, James
AU - Zhang, Yong Jie
AU - Petrucelli, Leonard
N1 - Funding Information:
This work was supported by the NIH (R35NS097273 to L.P.; P01NS084974 to D.W.D., T.F.G., Y.-J.Z., and L.P.; P01NS099114 to T.F.G. and L.P.; R01NS088689 to L.P.; and R21AG065854 and R01GM099836 to J.S.), Mayo Clinic Foundation (to L.P.), Amyotrophic Lateral Sclerosis Association (to T.F.G., L.P., J.S., and Y.-.J.Z.), Robert Packard Center for ALS Research at Johns Hopkins (to L.P. and J.S.), Target ALS Foundation (to T.F.G., L.P., J.S., and Y.-J.Z.), Biogen Idec (to L.P.), and AstraZeneca postdoctoral fellowship (to H.M.O.).
Publisher Copyright:
Copyright © 2020 The Authors, some rights reserved;
PY - 2020
Y1 - 2020
N2 - TAR DNA-binding protein 43 (TDP-43) inclusions are a pathological hallmark of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), including cases caused by G4C2 repeat expansions in the C9orf72 gene (c9FTD/ALS). Providing mechanistic insight into the link between C9orf72 mutations and TDP-43 pathology, we demonstrated that a glycine-arginine repeat protein [poly(GR)] translated from expanded G4C2 repeats was sufficient to promote aggregation of endogenous TDP-43. In particular, toxic poly(GR) proteins mediated sequestration of full-length TDP-43 in an RNA-independent manner to induce cytoplasmic TDP-43 inclusion formation. Moreover, in GFP-(GR)200 mice, poly(GR) caused the mislocalization of nucleocytoplasmic transport factors and nuclear pore complex proteins. These mislocalization events resulted in the aberrant accumulation of endogenous TDP-43 in the cytoplasm where it co-aggregated with poly(GR). Last, we demonstrated that treating G4C2 repeat–expressing mice with repeat-targeting antisense oligonucleotides lowered poly(GR) burden, which was accompanied by reduced TDP-43 pathology and neurodegeneration, including lowering of plasma neurofilament light (NFL) concentration. These results contribute to clarification of the mechanism by which poly(GR) drives TDP-43 proteinopathy, confirm that G4C2-targeted therapeutics reduce TDP-43 pathology in vivo, and demonstrate that alterations in plasma NFL provide insight into the therapeutic efficacy of disease-modifying treatments.
AB - TAR DNA-binding protein 43 (TDP-43) inclusions are a pathological hallmark of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), including cases caused by G4C2 repeat expansions in the C9orf72 gene (c9FTD/ALS). Providing mechanistic insight into the link between C9orf72 mutations and TDP-43 pathology, we demonstrated that a glycine-arginine repeat protein [poly(GR)] translated from expanded G4C2 repeats was sufficient to promote aggregation of endogenous TDP-43. In particular, toxic poly(GR) proteins mediated sequestration of full-length TDP-43 in an RNA-independent manner to induce cytoplasmic TDP-43 inclusion formation. Moreover, in GFP-(GR)200 mice, poly(GR) caused the mislocalization of nucleocytoplasmic transport factors and nuclear pore complex proteins. These mislocalization events resulted in the aberrant accumulation of endogenous TDP-43 in the cytoplasm where it co-aggregated with poly(GR). Last, we demonstrated that treating G4C2 repeat–expressing mice with repeat-targeting antisense oligonucleotides lowered poly(GR) burden, which was accompanied by reduced TDP-43 pathology and neurodegeneration, including lowering of plasma neurofilament light (NFL) concentration. These results contribute to clarification of the mechanism by which poly(GR) drives TDP-43 proteinopathy, confirm that G4C2-targeted therapeutics reduce TDP-43 pathology in vivo, and demonstrate that alterations in plasma NFL provide insight into the therapeutic efficacy of disease-modifying treatments.
UR - http://www.scopus.com/inward/record.url?scp=85090261306&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090261306&partnerID=8YFLogxK
U2 - 10.1126/SCITRANSLMED.ABB3774
DO - 10.1126/SCITRANSLMED.ABB3774
M3 - Article
C2 - 32878979
AN - SCOPUS:85090261306
SN - 1946-6234
VL - 12
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 559
M1 - , eabb3774
ER -